CoChat

Targeted CuFe2O4 hybrid nanoradiosensitizers for synchronous chemoradiotherapy

Salehiabar, Marziyeh, Ghaffarlou, Mohammadreza, Mohammadi, Ali, Mousazadeh, Navid, Rahimi, Hossein, Abhari, Fatemeh, Rashidzadeh, Hamid, Nasehi, Leila, Rezaeejam, Hamed, Barsbay, Murat, Ertas, Yavuz Nuri, Nosrati, Hamed, Kavetskyy, Taras, Danafar, Hossein · 2023 · Journal of Controlled Release
Cited by 56

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Multifunctional nanoplatforms based on novel bimetallic nanoparticles have emerged as effective radiosensitizers owing to their potential capability in cancer cells radiosensitization. Implementation of chemotherapy along with radiotherapy, known as synchronous chemoradiotherapy, can augment the treatment efficacy. Herein, a tumor targeted nanoradiosensitizer with synchronous chemoradiotion properties, termed as CuFe2O4@BSA-FA-CUR, loaded with curcumin (CUR) and modified by bovine serum albumin (BSA) and folic acid (FA) was developed to enhance tumor accumulation and promote the anti-cancer activity while attenuating adverse effects. Both copper (Cu) and iron (Fe) were utilized in the construction of these submicron scale entities, therefore strong radiosensitization effect is anticipated by implementation of these two metals. The structure-function relationships between constituents of nanomaterials and their function led to the development of nanoscale materials with great radiosensitizing capacity and biosafety. BSA was used to anchor Fe and Cu ions but also to improve colloidal stability, blood circulation time, biocompatibility, and further functionalization. Moreover, to specifically target tumor sites and enhance cellular uptake, FA was conjugated onto the surface of hybrid bimetallic nanoparticles. Finally, CUR as a natural chemotherapeutic agent was encapsulated into the developed bimetallic nanoparticles. With incorporation of all abovementioned stages into one multifunctional nanoplatform, CuFe2O4@BSA-FA-CUR is produced for synergistic chemoradiotherapy with positive outcomes. In vitro investigation revealed that these nanoplatforms bear excellent biosafety, great tumor cell killing ability and radiosensitizing capacity. In addition, high cancer-suppression efficiency was observed through in vivo studies. It is worth mentioning that co-use of CuFe2O4@BSA-FA-CUR nanoplatforms and X-ray radiation led to complete tumor ablation in almost all of the treated mice. No mortality or radiation-induced normal tissue toxicity were observed following administration of CuFe2O4@BSA-FA-CUR nanoparticles which highlights the biosafety of these submicron scale entities. These results offer powerful evidence for the potential capability of CuFe2O4@BSA-FA-CUR in radiosensitization of malignant tumors and opens up a new avenue of research in this area.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2022.12.004

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 56

Metadata

Authors
Salehiabar, M., Ghaffarlou, M., Mohammadi, A., Mousazadeh, N., Rahimi, H., Abhari, F., Rashidzadeh, H., Nasehi, L., Rezaeejam, H., Barsbay, M., Ertas, Y. N., Nosrati, H., Kavetskyy, T., & Danafar, H.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2023-01
Volume
353
Pages
850-863
ISSN
0168-3659 (ISSN-L)
OpenAlex
W4311808418
Cited by
56
References
2
FWCI
3.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted CuFe2O4 hybrid nanoradiosensitizers for synchronous chemoradiotherapy. https://app.cochat.ai/papers/10.1016/j.jconrel.2022.12.004
The paper
Salehiabar, M., Ghaffarlou, M., Mohammadi, A., Mousazadeh, N., Rahimi, H., Abhari, F., Rashidzadeh, H., Nasehi, L., Rezaeejam, H., Barsbay, M., Ertas, Y. N., Nosrati, H., Kavetskyy, T., & Danafar, H. (2023). Targeted CuFe2O4 hybrid nanoradiosensitizers for synchronous chemoradiotherapy. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2022.12.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.